Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

NCT02413736 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

255

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: Imatinib

Sponsor

Heikki Joensuu

Collaborators

[object Object]